These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17192509)

  • 1. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects.
    Schindler C; Brosnihan KB; Ferrario CM; Bramlage P; Maywald U; Koch R; Oertel R; Kirch W
    J Clin Pharmacol; 2007 Jan; 47(1):112-20. PubMed ID: 17192509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction.
    Schindler C; Guenther K; Hermann C; Ferrario CM; Schroeder C; Haufe S; Jordan J; Kirch W
    PLoS One; 2014; 9(9):e103909. PubMed ID: 25264877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
    Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
    Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.
    Herlitz H; Palmgren E; Widgren B; Aurell M
    Clin Sci (Lond); 2005 Sep; 109(3):311-7. PubMed ID: 15901242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
    Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
    McDonald JE; Padmanabhan N; Petrie MC; Hillier C; Connell JM; McMurray JJ
    Circulation; 2001 Oct; 104(15):1805-8. PubMed ID: 11591618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
    Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
    Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Interplay between the Renin Angiotensin System and Pacing Postconditioning Induced Cardiac Protection.
    Babiker F; Al-Jarallah A; Joseph S
    PLoS One; 2016; 11(11):e0165777. PubMed ID: 27814397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
    Burnier M; Hagman M; Nussberger J; Biollaz J; Armagnac C; Brouard R; Weber B; Brunner HR
    Hypertension; 1995 Apr; 25(4 Pt 1):602-9. PubMed ID: 7721404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of calycosin and irbesartan for their impact on renin angiotensin system in human umbilical vein endothelial cell.
    Li XL; Song RX; Lin X; Ma RX; Bai F; Yu J
    Minerva Med; 2015 Feb; 106(1):9-16. PubMed ID: 25423498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.
    Sakuta T; Morita Y; Satoh M; Fox DA; Kashihara N
    Arthritis Rheum; 2010 May; 62(5):1319-28. PubMed ID: 20213806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells.
    Wang D; Hirase T; Inoue T; Node K
    Biochem Biophys Res Commun; 2006 Aug; 347(2):394-400. PubMed ID: 16842760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
    Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
    J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress.
    Briones AM; Rodríguez-Criado N; Hernanz R; García-Redondo AB; Rodrigues-Díez RR; Alonso MJ; Egido J; Ruiz-Ortega M; Salaices M
    Hypertension; 2009 Jul; 54(1):142-9. PubMed ID: 19451411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
    Roksnoer LC; van Veghel R; de Vries R; Garrelds IM; Bhaggoe UM; Friesema EC; Leijten FP; Poglitsch M; Domenig O; Clahsen-van Groningen MC; Hoorn EJ; Jan Danser AH; Batenburg WW
    Kidney Int; 2015 Jul; 88(1):109-20. PubMed ID: 25830765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.
    Moreno M; Ramalho LN; Sancho-Bru P; Ruiz-Ortega M; Ramalho F; Abraldes JG; Colmenero J; Dominguez M; Egido J; Arroyo V; Ginès P; Bataller R
    Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G147-56. PubMed ID: 19056767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
    McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
    Toblli JE; Muñoz MC; Cao G; Mella J; Pereyra L; Mastai R
    Obesity (Silver Spring); 2008 Apr; 16(4):770-6. PubMed ID: 18239590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
    Ager EI; Wen SW; Chan J; Chong WW; Neo JH; Christophi C
    BMC Cancer; 2011 Jun; 11():274. PubMed ID: 21703011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.